Clinical Study of Desuzumab in the Treatment of Knee Osteoarthritis
Key facts
- Where
- Wuhan, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 45 and 75 years old?
Source: NCT06357741, who can take part
Where in China
- Wuhan Union HospitalWuhan, ChinaContact: Hongtao Tian, doctorTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Trial code
- NCT06357741
- Record updated
- 9 April 2025
- Original description
As an activator of inhibiting nuclear factor kB receptor, denosumab affects osteoclast differentiation and development by inhibiting OPG/RANKL-RANK bone regulatory axis pathway. Therefore, denosumab is widely used in the treatment of bone diseases such as osteoporosis. Osteoporosis is closely related to knee osteoarthritis. RANKL-RANK pathway also plays a key role in the pathogenesis of knee osteoarthritis. Therefore, the investigators propose the hypothesis that denosumab can effectively treat knee osteoarthritis.Read full original descriptionShow less
As an activator of inhibiting nuclear factor kB receptor, denosumab affects osteoclast differentiation and development by inhibiting OPG/RANKL-RANK bone regulatory axis pathway. Therefore, denosumab is widely used in the treatment of bone diseases such as osteoporosis. Osteoporosis is closely related to knee osteoarthritis. RANKL-RANK pathway also plays a key role in the pathogenesis of knee osteoarthritis. Therefore, the investigators propose the hypothesis that denosumab can effectively treat knee osteoarthritis.
Inclusion: patients with knee osteoarthritis whose inclusion criteria meet the "diagnostic criteria for arthritis" ; no drug contraindications ; aged between 45 and 75 ; committed to follow the research procedures, And cooperate with the •implementation of the whole process study ; the patient understands the relevant treatment process ; the patient has the ability to give informed consent ; The patient had not recently taken any medication that affected observation; the subjects must meet all the inclusion criteria to be eligible to participate in the study .
Exclusion: mental illness ; patients with malignant tumors; patients with other infectious diseases ; patients with metabolic bone disease, diabetes and hyperthyroidism; patients who cannot actively cooperate in the treatment; hypocalcemia.